]Use of funds
The proceeds from the Entitlement Offer will be used to fund the ongoing Phase 2 ACCENT trial in
pancreatic cancer to an Interim Analysis (expected in Q3 2024), as well as undertake production of
additional narmafotinib capsules and support a pilot Investigator Initiated trial in ovarian cancer
currently in planning.
To my best understanding and guess, another CR will occur after Interim Analysis ...hopefully at a decent price. Also as mentioned by another poster... R&D rebate should kick-in in October. Blue sky ahead if interim results confirm the efficacy.
Ann: Sustained Reduction in Tumour Size Seen In Pancreatic Trial, page-27
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $32.97M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 59706 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 6309 | 2 |
View Market Depth
| Last trade - 15.06pm 30/08/2024 (20 minute delay) ? |
| ATX (ASX) Chart |
Day chart unavailable